Skip to content
approvedImmune & Inflammation

Daptomycin

Also known as: Cubicin, Cubicin RF, LY146032, Daptomycin for Injection

Daptomycin (Cubicin) is a cyclic lipopeptide antibiotic derived from Streptomyces roseosporus, FDA-approved in 2003 for the treatment of serious gram-positive infections including MRSA (methicillin-resistant Staphylococcus aureus) bacteremia and complicated skin and soft tissue infections. It has a unique calcium-dependent mechanism of action that makes cross-resistance with other antibiotic classes extremely rare, establishing it as a cornerstone of treatment for multidrug-resistant gram-positive infections.

3 cited references·6 researched benefits

Quick Answer

Daptomycin (Cubicin) is a cyclic lipopeptide antibiotic FDA-approved for serious gram-positive infections including MRSA bacteremia and complicated skin infections. It kills bacteria through a unique calcium-dependent membrane depolarization mechanism with no cross-resistance to vancomycin or beta-lactams. Administered once daily intravenously, it has a half-life of 8-9 hours. Daptomycin should not be used for pneumonia as it is inactivated by pulmonary surfactant. CPK monitoring is required due to skeletal muscle toxicity risk.

Key Facts

Mechanism
Daptomycin requires calcium ions for its antibacterial activity. In the presence of physiological calcium concentrations, daptomycin oligomerizes and inserts its lipophilic tail into the gram-positive bacterial cytoplasmic membrane. This insertion forms ion-conducting channels that cause rapid depolarization of the membrane potential without cell lysis. The loss of membrane potential disrupts multiple essential cellular processes simultaneously: protein synthesis, DNA replication, RNA transcription, and ATP production all cease abruptly. This rapid, multi-target mechanism results in bactericidal killing and explains why resistance development is uncommon. Importantly, daptomycin is inactivated by pulmonary surfactant, which sequesters the lipopeptide and prevents membrane insertion, making it ineffective for pneumonia.
Research Status
approved
Half-Life
~8-9 hours
Molecular Formula
C₇₂H₁₀₁N₁₇O₂₆
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • FDA-approved first-line treatment for MRSA bacteremia and endocarditisstrong
  • Rapid concentration-dependent bactericidal activity against gram-positive pathogensstrong
  • No cross-resistance with vancomycin, beta-lactams, or linezolidstrong
  • Once-daily intravenous dosing improves convenience and compliance in serious infectionsstrong
  • Effective against vancomycin-resistant enterococci (VRE) infectionsmoderate
  • Low potential for driving Clostridioides difficile infection compared to other antibioticsmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous4 mg/kg once dailyOnce dailyFDA-approved dose for complicated skin and soft tissue infections (cSSTI)
Intravenous6 mg/kg once dailyOnce dailyFDA-approved dose for S. aureus bacteremia and right-sided endocarditis
Intravenous (high-dose)8-12 mg/kg once dailyOnce dailyOff-label high-dose regimen for VRE infections, left-sided endocarditis, and osteomyelitis; used in clinical practice

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Elevated creatine phosphokinase (CPK) indicating skeletal muscle effectscommon
  • Gastrointestinal effects including nausea, diarrhea, and constipationcommon
  • Eosinophilic pneumonia (rare but serious — discontinue immediately)serious
  • Rhabdomyolysis with concurrent statin therapy (avoid combination)serious
  • Peripheral neuropathy with prolonged coursesrare
  • Injection site reactionscommon

Frequently Asked Questions

Why can daptomycin not be used for pneumonia?
Daptomycin is inactivated by pulmonary surfactant, the phospholipid-rich substance that lines the alveoli and reduces surface tension in the lungs. Surfactant binds to daptomycin's lipophilic tail, preventing it from inserting into bacterial membranes. This was demonstrated in a clinical trial where daptomycin was non-inferior to other drugs for skin infections but failed in community-acquired pneumonia. It should never be used to treat any pulmonary infection regardless of pathogen susceptibility.
What monitoring is required during daptomycin therapy?
Weekly CPK (creatine phosphokinase) monitoring is mandatory during daptomycin therapy. CPK levels greater than 5-10 times the upper limit of normal or symptoms of myopathy (muscle pain, weakness, elevated CPK) warrant discontinuation. Concurrent statin therapy should be temporarily suspended during daptomycin treatment due to additive muscle toxicity risk. Renal function should also be monitored, with dose adjustment for creatinine clearance below 30 mL/min.
How does daptomycin compare to vancomycin for MRSA?
Daptomycin offers several advantages over vancomycin for MRSA infections: faster bactericidal killing (vancomycin is slowly bactericidal), once-daily dosing versus twice-daily, no need for trough level monitoring (though area-under-curve monitoring is now recommended for vancomycin), and better outcomes in vancomycin MIC "creep" scenarios. Daptomycin is now considered the preferred agent for MRSA bacteremia in many guidelines, particularly when vancomycin MIC is at the upper limit of susceptibility.

References

  1. 1
    Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections(2003)PubMed ↗
  2. 2
    Daptomycin for the treatment of bacteraemia and endocarditis caused by Staphylococcus aureus(2006)PubMed ↗
  3. 3
    Mechanism of action of daptomycin: calcium-dependent membrane depolarization(2002)PubMed ↗

Latest Research

Last updated: 2026-02-19